Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package
Brent Saunders’ H2 2017 strategy to preserve control of the Restasis patents may be under assault from every angle, forcing the company to restructure ahead of the likely loss of its lucrative franchise, but that didn’t stop Allergan CEO Brent Saunders from picking up a huge hike in compensation for the year.
The company’s proxy statement shows Saunders took home a pay packet worth $32.8 million — about 8 times what he earned the year before. And with a raft of new SEC filings today, it’s clear that Saunders scored high relative to the execs in charge of much, much larger pharma companies with a better track record on share value.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
